DIAGENS-B (02526) shares have surged over 9% again, reaching an intraday high of HK$440, setting a new record since its listing. As of writing, the stock is up 8.37% to HK$432.4, with a turnover of HK$8.5436 million.

The catalyst for this movement is the recent official launch of the iMedLoop™ global medical imaging data platform by the company at the Diaoyutai State Guesthouse. This event marks the concrete implementation of its foundational capability development. It represents more than a simple product release; it is a watershed moment for the medical AI industry, signaling a shift from project-based, "artisanal workshop" exploration towards "industrial assembly line" style mass production.

As the industry's key challenge evolves from "model accuracy" to "production efficiency," the company is attempting to define the core competitive logic for the next phase of medical AI through its deep restructuring of the medical imaging data value chain.

From a capital markets valuation perspective, the company's potential value ceiling is quantifiable. Public data indicates the long-term market space for integrated platforms in China encompassing medical imaging data, model training, and clinical services exceeds HK$100 billion.

The iMedLoop platform establishes a rare, fully closed-loop productivity foundation within the industry. It addresses the development needs for models across thousands of hospitals and tens of thousands of disease types. Coupled with multiple revenue streams, including MaaS subscriptions, model licensing, and medical device registration commercialization, the company possesses the fundamental industrial strength and growth potential to support a market valuation in the hundreds of billions over the long term. It is also a scarce platform-type stock on the Hong Kong market with potential for such a scale within the large model and 18A medical AI sectors.